Sirion Biotech, a viral vector platform company creating viral vector solutions for industry and academic partners headquartered in Germany, has committed to opening a new office in the vicinity of Boston.
Sirion is working with the Massachusetts Life Sciences Center (MLSC) to locate lab and office space for the company, which will prove to be a pivotal step in Sirion’s U.S. expansion. Sirion’s office in the Boston area will allow direct access to Massachusetts' life science community, which includes an increasing number of biotechnology companies and academic researchers working to develop gene therapies and vaccines for a range of diseases.
"We appreciate the assistance from Massachusetts Life Sciences Center in helping us begin building our U.S. operations in the Boston area," said Dieter Lingelbach, chief operating officer of Sirion Biotech. "We are a growing company, planning to build on the success we've had in Europe, Israel and Japan, as we collaborate with many companies pioneering gene therapies."
Sirion provides customizable versions of all three major viral vector types, adenovirus, adeno-associated virus and lentivirus, and offers experience in transduction of various cell lines, an essential piece of all genetic applications.